<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335210">
  <stage>Registered</stage>
  <submitdate>1/03/2010</submitdate>
  <approvaldate>8/03/2010</approvaldate>
  <actrnumber>ACTRN12610000195055</actrnumber>
  <trial_identification>
    <studytitle>Effect Of Micronised Progesterone On Endometrial Receptivity</studytitle>
    <scientifictitle>Investigation Of Endometrial Receptivity Parameters At Mid Secretory Phase When Micronised Progesterone Added During Luteal Phase in infertile Patients with Polycistic Ovaries and Unexplained Infertility</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>infertile patients with polycystic ovaries and unexplained infertility</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fertility including in vitro fertilisation</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>patients will take oral clomiphene citrate of 2 tablets(100 mg) each day,beginning at fifth day of menstruel cycle for five days.stusy group will then take micronised progesterone , 2 capsule of 200 mg(400 mg/day)beginning just after ovulation for 14 days</interventions>
    <comparator>control group will take clomiphene citrate for 5 days just like treatment group in preovulatory phase,but will not take progesterone after the ovulation</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>We will take endometrrial biopsies from all participants by pipelle at mid-secretory period and fixe with formaline and then embed in paraffin block.After all samples collected immunohistocchemical staining and investigation and scorring under microscopy will be performed for the following;
Estrogen receptor
Progesterone receptor
Glycodelin
Interleukine(IL) 11
Leukaemia inhibitory factor (LIF), all these will be obtained as commercial antibody kits by abcam.</outcome>
      <timepoint>at 2 months post-intervention</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>chemical pregnancy rate;will be detected by blood beta human chorionic gonadotrophin(HCG) measurement after the menstreal delay for 3 days
clinical pregnancy rate; which will be detected by transvaginal ultrasonography after the menstruel delay of 7 days.</outcome>
      <timepoint>at 2 months post-intervention</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>INFERTILE PATIENTS OF POLYCYSTIC OVARIES AND UNEXPLAINED INFERTILITY
20-39 YEARS OLD
NO SYSTEMIC DISEASES</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>39</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>INFERTILITY OTHER THAN polycystic ovaries(PCO) AND UNEXPLAINED,SYSTEMIC DISEASES,DRUG USERS,OVARIAN OR ENDOMETRIAL PATHOLOGIES SUCH AS MYOMA,ENDOMETRIOSIS</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>15/03/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>ISTANBUL UNIVERSITY RESEARCH FUND</primarysponsorname>
    <primarysponsoraddress>Vatan caddesi,ISTANBUL UNIVERSITY RESEARCH FUND,Fatih,ISTANBUL,TURKEY
area code:34303</primarysponsoraddress>
    <primarysponsorcountry>Turkey</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>ISTANBUL UNIVERSITY RESEARCH FUND</fundingname>
      <fundingaddress>Vatan caddesi,ISTANBUL UNIVERSITY RESEARCH FUND,Fatih,ISTANBUL,TURKEY
area code:34303</fundingaddress>
      <fundingcountry>Turkey</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>NONE</sponsorname>
      <sponsoraddress>NONE</sponsoraddress>
      <sponsorcountry>Turkey</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>primary purpose is to investigate the effect of micronised progesterone as luteal phase support on endometrium receptivity in polycystic ovaries and unexplained infertility patients.Gylcodelin,leukemia inhibitory factor and interleukin 11 are well previously defined cytokines that related with embryo implantation especially at mid secretory phase of the cycle</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>yavuz aydin</name>
      <address>Hobyar mahallesi,OBSTETRICS AND GYNECOLOGY,CERRAHPASA MEDICAL FACULTY,Fatih,ISTANBUL TURKEY
area code:34317</address>
      <phone>+902124951616</phone>
      <fax />
      <email>yavuzay@istanbul.edu.tr</email>
      <country>Turkey</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>YAVUZ AYDIN</name>
      <address>Hobyar mahallesi,OBSTETRICS AND GYNECOLOGY,CERRAHPASA MEDICAL FACULTY,Fatih,ISTANBUL TURKEY
area code:34317</address>
      <phone>902124143000-21442</phone>
      <fax />
      <email>yavuzay@istanbul.edu.tr</email>
      <country>Turkey</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>